Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

Trial Profile

Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Disufenton (Primary)
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Oblato
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 jun 2017 to 1 Nov 2018.
    • 22 Sep 2017 Planned primary completion date changed from 1 jun 2017 to 1 Sep 2018.
    • 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top